Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | REGN4018 + REGN5668 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
REGN4018 | REGN-4018|REGN 4018|Ubamatamab | CD3 Antibody 97 MUC16 Targeted Therapy 10 | REGN4018 is a bispecific antibody that binds MUC16 (CA125) on tumor cells and CD3 on T-cells to stimulate T-cell killing of MUC16-expressing tumor cells (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1777, PMID: 31217340). | |
REGN5668 | REGN 5668|REGN-5668 | MUC16 Targeted Therapy 10 | REGN5668 is a bispecific monoclonal antibody that targets both CD28 and MUC16 (CA125), resulting in cross-linking of CD28-positive T-cells to MUC16-expressing tumor cells, potentially leading to enhanced cytotoxic response against MUC16-positive tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04590326 | Phase Ib/II | REGN4018 + REGN5668 Cemiplimab + REGN5668 | Study of REGN5668 Administered in Combination With Cemiplimab or REGN4018 in Adult Women With Recurrent Ovarian Cancer. | Recruiting | USA | BEL | 0 |